KemPharm Revenue and Competitors
Estimated Revenue & Valuation
- KemPharm's estimated annual revenue is currently $28.4M per year.
- KemPharm's estimated revenue per employee is $498,772
- KemPharm's total funding is $75.8M.
Employee Data
- KemPharm has 57 Employees.
- KemPharm grew their employee count by 33% last year.
KemPharm Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $28.4M | 57 | 33% | $75.8M | N/A |
#2 | $1.2M | 6 | -73% | N/A | N/A |
#3 | $26.3M | 131 | 3% | N/A | N/A |
#4 | $33.4M | 166 | 2% | N/A | N/A |
#5 | $1073.9M | 5343 | 8% | N/A | N/A |
#6 | $9M | 45 | 10% | N/A | N/A |
#7 | $20.5M | 102 | 52% | N/A | N/A |
#8 | $20.1M | 100 | 37% | N/A | N/A |
#9 | $9.2M | 46 | 10% | N/A | N/A |
#10 | $3M | 15 | -56% | N/A | N/A |
What Is KemPharm?
KemPharm, Inc. is an early phase biopharmaceutical company located in the Iowa City, IA area near the campus of the University of Iowa. We are focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
keywords:N/A
$75.8M
Total Funding
57
Number of Employees
$28.4M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
KemPharm's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP Research & Development | Reveal Email/Phone |
2 | TitleVP Clinical Operations | Reveal Email/Phone |
3 | VP, Corporate Controller | Reveal Email/Phone |
4 | Chief Financial Officer, Secretary and Treasurer | Reveal Email/Phone |
5 | VP, Head Nonclinical Development | Reveal Email/Phone |
6 | Senior Finance Assistant | Reveal Email/Phone |
7 | Student Assistant | Reveal Email/Phone |
8 | VP, Scientific Affairs | Reveal Email/Phone |
KemPharm News
SDX, KemPharm's proprietary prodrug of d-methylphenidate (d-MPH), is the sole active pharmaceutical ingredient (API) in KP1077, which KemPharm...
KemPharm, Inc. KMPH announced that it has initiated dosing in a phase I study to evaluate its d-methylphenidate prodrug,...
KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS)...
Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused ...
Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of propri ...
Other Companies in Coralville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.4M | 57 | -8% | N/A |
#2 | $5.2M | 58 | 5% | N/A |
#3 | $10M | 62 | -5% | N/A |
#4 | $9.3M | 69 | 5% | N/A |
#5 | $17.5M | 77 | 5% | N/A |